PO.BCS01.07 · 生物信息与计算

可解释组织形态学特征与分子标志物的关联:一项计算组织学人工智能(CHAI)生物标志物开发平台分析

Association of interpretable histomorphic features with molecular markers: A Computational Histology Artificial Intelligence (CHAI) biomarker development platform analysis

海报缩略图:可解释组织形态学特征与分子标志物的关联:一项计算组织学人工智能(CHAI)生物标志物开发平台分析
编号 1453 展板 16 时间 4/20 09:00–12:00 区域 Section 4 主讲 Haochen Zhang, PhD
分会场 Digital Pathology 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Asit Tarsode1, Haochen Zhang1, Viswesh Krishna1, Vrishab Krishna1, Snehal S. Sonawane1, Lesli A. Kiedrowski1, Trevor J. Royce1, Anirudh Joshi1, Richard M. Goldberg2, Eric A. Collisson3

1Valar Labs, Palo Alto, CA,2Physician-in-Chief/Internal Medicine, West Virginia University Randolph Cancer Center, Morgantown, WV,3Hematology/Oncology, UCSF, San Francisco, CA

摘要 Abstract

中文摘要
背景:需要生物标志物来指导精准肿瘤学。理想情况下,相关工具应具有快速周转能力并能整合到现有工作流程中。分析常规苏木精和伊红(H&E)染色全切片图像(WSI)上特征的计算病理学,为生物标志物发现提供了一个易于使用的系统。计算组织学人工智能(CHAI)平台已被验证可预测多种实体瘤类型的临床结局终点。为探索组织形态学特征与分子标志物之间尚未明确的重叠,我们评估了CHAI特征与多重免疫荧光(MIF)标志物之间的关联。 方法:CHAI平台构建于深度学习模型之上,这些模型在>25,000张泛癌种H&E WSI上训练,并纳入了>500,000个病理学家标注的细胞核和1亿µm²组织,细胞核和组织分割的宏平均AUC为0.99。这些模型处理H&E WSI,分割全面的癌症相关细胞和组织类型,并量化>30,000个代表癌症生物学标志的组织形态学特征(例如细胞核大小和形状、空间排列、免疫浸润、间质密度)。在来自ORION数据集的41张具有匹配MIF扫描的结直肠癌WSI上,通过计算CHAI预测目标与匹配MIF标志物密度之间的Pearson相关系数,评估了CHAI细胞/组织分型性能与MIF的对比。 结果:在289,619个200 x 200 µm²组织切块中,比较CHAI分割细胞核与MIF DAPI的细胞分割相关性为0.899(95% CI 0.898, 0.900)。细胞分型相关性方面,CHAI预测的上皮细胞与MIF细胞角蛋白(CK)为0.642(0.640, 0.644),CHAI泛白细胞与MIF CD45为0.587(0.584, 0.590)。组织分型相关性方面,CHAI肿瘤-上皮区域与MIF CK为0.656(0.653, 0.658),CHAI间质区域与MIF平滑肌肌动蛋白为0.543(0.541, 0.546)。所有相关性均具有统计学显著性(p<0.001)。 结论:CHAI平台以高准确度测量H&E WSI的组织形态学特征;它捕捉了肿瘤微环境的诸多方面,这些方面与MIF捕获的分子标志物显示出显著重叠,同时也识别出可进一步探索这些正交模态互补性的领域。这项工作凸显了CHAI系统作为一种新型生物标志物开发模态的生物学基础,具有生物医学研究和临床应用的潜力。
查看英文原文 English abstract
Background: Biomarkers are needed to guide precision oncology. Ideally, tools have rapid turnaround and integrate into existing workflows. Computational pathology analyzing features on routine hematoxylin and eosin (H&E) stained whole slide images (WSI) provide an accessible system for biomarker discovery. The Computational Histology Artificial Intelligence (CHAI) platform has been validated to predict clinical outcome endpoints across multiple solid tumor types. To explore the unknown overlap of histomorphic features with molecular markers, we assessed associations of CHAI features with markers from multiplex immunofluorescence (MIF). Methods: The CHAI platform was built on deep learning models trained on >25,000 pan cancer H&E WSI and incorporates >500,000 pathologist annotated nuclei and 100 million μm² tissue, with macro AUC 0.99 for nuclei and tissue segmentation. These models process H&E WSIs, segment comprehensive cancer-relevant cell and tissue types and quantify >30,000 histomorphologic features representing hallmarks of cancer biology (e.g. nuclei size and shape, spatial arrangement, immune infiltration, stromal density). On 41 colorectal cancer WSIs with matched MIF scans from the ORION dataset, CHAI cell/tissue-typing performance was evaluated against MIF by calculating Pearson correlation coefficient between the densities of CHAI's predicted target and matched MIF markers. Results: Across 289,619 200 x 200 μm² tissue patches, cell segmentation correlation comparing CHAI-segmented nuclei vs MIF DAPI was 0.899 (95% CI 0.898, 0.900). Cell typing correlation was 0.642 (0.640, 0.644) for CHAI-predicted epithelial cells vs MIF cytokeratin (CK) and 0.587 (0.584, 0.590) for CHAI pan-leukocyte vs MIF CD45. Tissue typing correlation was 0.656 (0.653, 0.658) for CHAI tumor-epithelial regions vs MIF CK and 0.543 (0.541, 0.546) for CHAI stromal regions vs MIF smooth muscle actin. All correlations were statistically significant (p<0.001). Conclusion: The CHAI platform measures histomorphic features from H&E WSI at high accuracy; it captures facets of the tumor microenvironment that showed significant overlaps with molecular markers captured by MIF, while also identifying areas to further explore complementarity in these orthogonal modalities. This work underscores the biologic basis of the CHAI system as a novel modality for biomarker development with potential for biomedical research and clinical applications.
利益披露 Disclosure
A. Tarsode, Valar Labs Employment. H. Zhang, Valar Labs Employment. Revolution Medicines Stock. Elly Lily Stock. V. Krishna, Valar Labs Employment. V. Krishna, Valar Labs Employment. S. S. Sonawane, Valar Labs Employment. L. A. Kiedrowski, Valar Labs Employment. T. J. Royce, Valar Labs Employment. A. Joshi, Valar Labs Employment.

← 返回 AACR 2026 检索